Cargando…
Development of encorafenib for BRAF-mutated advanced melanoma
PURPOSE OF REVIEW: To describe the pharmacological properties, preclinical and clinical data of the novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)-inhibitor encorafenib (LGX818) and to compare these with established BRAF-inhibitors in the treatment of locally advanced or metastatic melan...
Autores principales: | Koelblinger, Peter, Thuerigen, Olaf, Dummer, Reinhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815646/ https://www.ncbi.nlm.nih.gov/pubmed/29356698 http://dx.doi.org/10.1097/CCO.0000000000000426 |
Ejemplares similares
-
Intralesional therapy for advanced melanoma: promise and limitation
por: Agarwala, Sanjiv S.
Publicado: (2015) -
Cutaneous angiosarcoma: update on biology and latest treatment
por: Ishida, Yoshihiro, et al.
Publicado: (2018) -
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma
por: Ellingsen, Espen Basmo, et al.
Publicado: (2023) -
Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy
por: D’Alise, Anna Morena, et al.
Publicado: (2023) -
Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2016)